Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study <scp>III</scp> ): An Investigator‐Initiated, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial

In this underpowered study, there was no statistically significant treatment difference in overall change in FVC-% between groups. MMF+PFD was not as well tolerated as MMF+PLA.

Authors

Institutions

Publication Details

Journal
ACR Open Rheumatology
Published
2025-11-26
DOI
https://doi.org/10.1002/acr2.70126
Citations
1
Primary Topic
Systemic Sclerosis and Related Diseases
Type
article
Field-Weighted Citation Impact
1.47

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study III ): An Investigator‐Initiated, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial

Michael D. Roth, Marcin A. Trojanowski, Gary Matthew Hunninghake, Mary Beth Scholand et al.
1 citations
ACR Open Rheumatology
Systemic Sclerosis and Related Diseases
1.47
article

Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study III ): An Investigator‐Initiated, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial

Michael D. Roth, Marcin A. Trojanowski, Gary Matthew Hunninghake, Mary Beth Scholand, Ganesh Raghu, Maureen D. Mayes, Richard McLain, R. Boente, Jane E. Dematte, Eric C. Kleerup, Iván O. Rosas, Aryeh Fischer, Cathie Spino, Jonathan Goldin, Elana J. Bernstein, Virginia Steen, Airi Harui, Vivien Hsu, Donald P. Tashkin, Vivek Nagaraja, Grace Hyun J. Kim, Paul F. Dellaripa, Dinesh Khanna, Robyn T. Domsic, Jessica Gordon, Richard M. Silver, Robert W. Simms, Grace Ibrahim, Joyce Lee, Suiyuan Huang, Yi‐Hsuan Tu, S. Samuel Weigt
article en
1 citations

Abstract

In this underpowered study, there was no statistically significant treatment difference in overall change in FVC-% between groups. MMF+PFD was not as well tolerated as MMF+PLA.

ACR Open RheumatologyVol. 7(12)
Rutgers, The State University of New Jersey (US), Boston University (US), Northwestern University (US), Hospital for Special Surgery (US), Brigham and Women's Hospital (US), Harvard University (US), Medical University of South Carolina (US), University of California, Los Angeles (US), Eli Lilly (United States) (US), University of Pittsburgh (US), Georgetown University (US), University of Washington (US), University of Utah (US), University of Michigan (US), Columbia University Irving Medical Center (US), Georgetown University Medical Center (US), Johnson University (US), Mayo Clinic in Arizona (US), The University of Texas Health Science Center (US), Indiana University School of Medicine, University of Colorado Anschutz Medical Campus (US), Indiana University – Purdue University Indianapolis (US), Seattle University (US)
Massachusetts General Hospital, Genentech
Openalex Percentile: Top 13%
Systemic Sclerosis and Related Diseases
1.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.